South Korea Begins Preliminary Review of AstraZeneca's COVID-19 Vaccine Candidate - COVID-19 Clinical Trial
Breaking News | COVID-19

South Korea Begins Preliminary Review of AstraZeneca’s COVID-19 Vaccine Candidate

South Korea’s food and drug ministry said on Tuesday it had begun a preliminary review of a COVID-19 vaccine being developed by AstraZeneca PLC for potential fast-track approval. The Ministry of Food and Drug Safety said in a statement that it had formed a screening team to review the vaccine candidate, with an application for formal approval expected in 90 days under its rapid approval program for COVID-19 treatments and vaccines.

The team is reviewing the vaccine’s non-clinical test data, the ministry said. The ministry added that it had given a green light to some 26 clinical trials for COVID-19 treatments and vaccines as of Monday, by entities such as pharmaceutical companies Celltrion Inc and Genexine Inc, with seven completed and 19 ongoing.

Doctors Question FDA Approval of Gilead’s COVID-19 Treatment and Say it has Limited Benefits

The Food and Drug Administration’s decision to grant a full approval to Gilead Sciences Inc.’s remdesivir is raising questions about the broader value of a drug that has been praised for being “first” but may only provide limited clinical benefits. It’s the first COVID-19 treatment to receive an FDA approval during the pandemic.

“The balance of the data shows that it is providing a benefit,” Dr. Scott Gottlieb, a former FDA commissioner, told Squawk Box Friday morning. “We have to be comfortable with singles and doubles when it comes to developing drugs against COVID right now. We rushed a lot of medicines into clinical development, not necessarily optimizing them. This is sort of the first generation of medicines. Nothing, probably, is going to be a home run.”

Share this:

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.